High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity

The American Journal of Medicine
E FreiG P Canellos

Abstract

Methotrexate (MTX) in high doses (3 to 7.5 g/m2) with leucovorin rescue (HDMTX-LCV) can be delivered on a weekly basis in a setting of proper pharmacologic monitoring. Myelosuppression occurs in 28 per cent of the patients and in 8 per cent of the courses and usually results from delayed MTX excretion secondary to mild reversible nephrotoxicity. The incidence of tumor regression was 50 per cent in head and neck cancer; 59 per cent in non-Hodgkin's lymphoma; 40 per cent in small cell lung cancer; 24 to 50 per cent in breast cancer and 50 per cent in osteogenic carcinoma, for an over-all response rate of 39 per cent (70 of 178) in patients with disseminated cancer. HDMTX-LCV is not recommended for the conventional treatment of metastatic cancer because of the potential for toxicity and the fact that the response rates cited are probably not superior to those which can be achieved by conventional doses of MTX. However, the relative lack of myelosuppression and mucositis, when compared to conventional unrescued MTS, and the achievement of therapeutic concentrations of MTX in the central nervous system with the HDMTX-LCV program have led to its incorporation into clinical trials of combination chemotherapy.

References

Sep 22, 1977·The New England Journal of Medicine·R G StollerB A Chabner
Jan 1, 1978·Journal of the National Cancer Institute·E FreiH Watts
Jul 24, 1975·The New England Journal of Medicine·W R ShapiroB M Mehta
Jan 1, 1965·Scandinavian Journal of Clinical and Laboratory Investigation·C Slot
Feb 1, 1958·A.M.A. Archives of Internal Medicine·J A WHITESIDEJ H BURCHENAL

❮ Previous
Next ❯

Citations

Mar 29, 2002·Survey of Ophthalmology·Russell W ReadNarsing A Rao
Feb 21, 1981·British Medical Journal·R L WoodsM H Tattersall
Aug 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brigitte C WidemannPeter C Adamson
Nov 1, 1986·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·F Ries, J Klastersky
Jan 31, 2004·Pediatric Blood & Cancer·Irene AquerretaLuis Sierrasesúmaga
Jan 26, 2010·Biochimica Et Biophysica Acta·Nitin Kumar AgarwalHassan Dihazi
Jan 15, 2008·Journal of Clinical Pharmacology·Marc PhillipsSuzanne Ward
Mar 2, 2011·Journal of Molecular Recognition : JMR·Jordan P VolpatoJoelle N Pelletier
Jul 1, 2010·Cell Biochemistry and Function·Premila AbrahamSuganthy Rabi
Mar 1, 1983·Cancer Treatment Reviews·J H Schornagel, J G McVie
Mar 1, 1982·Cancer Treatment Reviews·R B Weiss, D S Poster
Jul 21, 2015·Journal of the American Academy of Dermatology·Julie DelyonOlivier Chosidow
Jul 1, 1987·The Journal of the American Dental Association·R J KanasG W DeBoom
Jun 28, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jakob K AnningaR Maarten Egeler
Jun 24, 2006·The Oncologist·Brigitte C Widemann, Peter C Adamson
May 20, 2020·International Journal of Molecular Sciences·Przemysław KoźmińskiEwa Gniazdowska
Sep 1, 1989·British Journal of Clinical Pharmacology·P O GreinerJ M Cheron
Nov 3, 1983·The New England Journal of Medicine·J JolivetB A Chabner
May 28, 2008·Cancer Chemotherapy and Pharmacology·Myke R Green, Marc C Chamberlain
Nov 21, 2009·Expert Opinion on Biological Therapy·Daniel M Patterson, Siow Ming Lee
Aug 24, 2012·International Journal of Toxicology·Selvinaz DalakliogluArda Tasatargil
Jul 15, 2015·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Tracy WiczerKami Maddocks
Mar 15, 1989·Cancer·W A Bleyer
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·M A BunniR Stuart
Apr 1, 1984·The Journal of Laryngology and Otology·M SuzukiR Etoh
Jan 1, 1988·Seminars in Surgical Oncology·K H Antman, A D Elias
Jan 1, 1982·Medical and Pediatric Oncology·M F LeahyT C Hall
Jul 1, 1984·The Journal of Urology·I D GoldbergW D Bloomer
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C D Flombaum, P A Meyers
May 24, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ronald L Snyder
Oct 17, 2009·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Haitham W Tuffaha, Suha Al Omar
Jan 1, 1986·Cancer Investigation·T D Shenkenberg, C A Coltman
Jan 1, 1989·European Journal of Clinical Pharmacology·G DerayC Jacobs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.